Combinations of a long-acting β₂ agonist; is it BI-1744-CL?

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.17, Iss.11, 2007-11, pp. : 1401-1404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New steroids and steroid–longacting β₂agonist combinations

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 4, 2003-04 ,pp. : 557-561

Informa Healthcare

Access to resources Recommend Favorite

Long-acting β₂ agonists

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite

Indacaterol: a new long-acting β₂-agonist in the management of chronic obstructive pulmonary disease

By Steiropoulos Paschalis Papanas Nikolaos Nena Evangelia Bouros Demosthenes

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1015-1029

Informa Healthcare

Access to resources Recommend Favorite

New long-acting β₂-agonists

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 9, 2004-09 ,pp. : 1385-1388

Informa Healthcare

Access to resources Recommend Favorite

The Impact of Nonadherence to Inhaled Long-Acting β 2 -Adrenoceptor Agonist/Corticosteroid Combination Therapy on Healthcare Costs in Difficult-to-Control Asthma

By O'Neill Ciaran Gamble Jacqui Lindsay John T. Heaney Liam G.

Pharmaceutical Medicine, Vol. 25, Iss. 6, 2011-12 ,pp. : 379-385

Adis International

Access to resources Recommend Favorite